Bausch + Lomb Corporation (NYSE:BLCO) Stock Has Average Price Target of $20.83

Shares of Bausch + Lomb Corporation (NYSE:BLCO – Get Free Report) have been given an average recommendation of “Hold” by the fifteen ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $20.83.

Several research firms have recently weighed in on BLCO. Leerink Partners initiated coverage on shares of Bausch + Lomb in a report on Wednesday, September 9th. They issued an “outperform” rating and a $24.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on Bausch + Lomb from $16.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, October 29th. Wells Fargo & Company boosted their target price on Bausch + Lomb from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 29th. Weiss Ratings upgraded Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a report on Tuesday, September 15th.

Get Our Latest Stock Report on BLCO

Bausch + Lomb Stock Up 0.1%

Bausch + Lomb stock opened at $21.11 on Wednesday. The firm has a market capitalization of $7.56 billion, a price-to-earnings ratio of -68.09, a price-to-earnings-growth ratio of 0.56 and a beta of 0.52. The firm’s fifty day moving average price is $17.98 and its two-hundred day moving average price is $16.86. Bausch + Lomb has a 1-year low of $14.44 and a 1-year high of $21.40. The company has a current ratio of 1.56, a quick ratio of 1.04 and a debt-to-equity ratio of 0.78.

Bausch + Lomb (NYSE:BLCO – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.13. The business had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a positive return on equity of 5.01% and a negative net margin of 2.05%. Bausch + Lomb’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.18 EPS. On average, equities research analysts predict that Bausch + Lomb will post 0.94 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Bausch + Lomb news, CAO Frederick Munsch sold 112,015 shares of Bausch + Lomb stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $20.48, for a total transaction of $2,294,067.20. Following the transaction, the chief accounting officer directly owned 45,831 shares of the company’s stock, valued at approximately $938,618.88. This trade represents a 70.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.45% of the stock is owned by insiders.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds have recently modified their holdings of the company. R Squared Ltd lifted its position in Bausch + Lomb by 46.0% during the 3rd quarter. R Squared Ltd now owns 17,452 shares of the company’s stock valued at $297,000 after acquiring an additional 5,502 shares during the period. State of Wyoming boosted its holdings in Bausch + Lomb by 6.9% in the third quarter. State of Wyoming now owns 13,772 shares of the company’s stock worth $234,000 after acquiring an additional 887 shares in the last quarter. Beach Point Capital Management LP purchased a new stake in Bausch + Lomb during the 3rd quarter valued at about $5,882,000. Counterpoint Mutual Funds LLC purchased a new stake in Bausch + Lomb during the 3rd quarter valued at about $670,000. Finally, Roxbury Financial LLC purchased a new stake in Bausch + Lomb during the 3rd quarter valued at about $33,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

(Get Free Report)

Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.

Further Reading

Analyst Recommendations for Bausch + Lomb (NYSE:BLCO)

Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.